COVID-19: Considerations about immune suppression and biologicals at the time of SARS-CoV-2 pandemic

paythelady.612 shared this article with you from Inoreader COVID-19: Considerations about immune suppression and biologicals at the time of SARS-CoV-2 pandemic Μέσω pubmed: "world j clin cases"... World J Clin Cases. 2021 Jul 16;9(20):5352-5357. doi: 10.12998/wjcc.v9.i20.5352. ABSTRACT The extent of the profound immunological and nonimmunological responses linked to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection is currently being investigated worldwide due to the large burden associated with death due to SARS-CoV-2 and the short-term consequences of coronavirus disease 2019 (COVID-19). It has been hypothesized that patients on immunosuppressive treatments, including biologics, may have an augmented risk of being infected by SARS-CoV-2; however, there are currently no definitive data about biological drugs and COVID-19 in immune-mediated inflammatory diseases. Current epidemiological models developed to understand how long the COVID-19 epidemic may last are not conclusive and range from sustained epidemics to complete elimination. Nevertheless, even in the best-case scenario of apparent elimination, there is concordance about a possible contagion resurgence as late as 2024. Therefore, knowledge of the impact of SARS-CoV-2 on immune-mediated diseases and among patients treated with biologicals, together with the results of novel and promising COVID-19 treatment strategies targeting the virus and the host immune response (or both), will help us to best manage our patients during this pandemic over the next few years. PMID:34307589 | PMC:PMC8281435 | DOI:10.12998/wjcc.v9.i20.5352 View on the web Inoreader. Take back control of your news feed. Follow us on Twitter and Facebook.